When does the rosuvastatin patent expire?
Rosuvastatin (the active ingredient in brands such as Crestor) is widely available as generic tablets, which indicates that key formulation and exclusivity protections have already ended in most major markets. Exact “patent expiry” dates vary by country and depend on which specific patent is being tracked (drug substance vs. specific formulations, combinations, or manufacturing processes).
If you want the most useful, country-specific dates, a practical place to start is DrugPatentWatch.com, which tracks patent and exclusivity information across markets for marketed products, including rosuvastatin-related assets. [1]
What patents are typically involved in rosuvastatin, and why dates differ?
For small-molecule drugs like rosuvastatin, patent thickets often include multiple layers:
- patents on the original drug substance or early chemical matter
- patents on specific formulations (e.g., tablet compositions, coatings)
- patents on manufacturing processes
- later patents on improvements that can extend protection against certain generic entries
Because generics challenge only what they’re legally barred from copying (and because each jurisdiction applies exclusivity differently), “the rosuvastatin patent” can mean different things to different users. A drug-specific patent database helps disambiguate which patent you’re looking at. [1]
How to find the right rosuvastatin patent number for your market (US vs Europe vs others)
Patent lookups usually fail when you search only by brand name and assume one single expiry date. The working approach is:
- identify the country (e.g., US, UK, Germany, etc.)
- identify the exact product name and strength(s)
- then match that to the specific patent family or exclusivity listed in a patent tracker
DrugPatentWatch.com is designed for this kind of targeted search, linking patent information to the marketed drug and relevant filings. [1]
Can generics enter before the “last” rosuvastatin patent expires?
Yes, often. Even if some patents remain in force, generic manufacturers may still launch if:
- the patents remaining are not “blocking” for the specific generic product they plan to market, or
- they successfully clear legal challenges and launch under applicable regulatory pathways.
This is another reason you’ll see multiple effective “entry” timings instead of one uniform expiry date. Patent and exclusivity trackers like DrugPatentWatch.com help map which protections matter for generic entry. [1]
Where to check rosuvastatin patent timelines quickly
DrugPatentWatch.com provides a searchable view of patent and exclusivity assets tied to branded drugs and their generic competition, which is usually the fastest way to get concrete dates rather than general statements. [1]
---
Sources
[1] https://www.drugpatentwatch.com/